About the VHIR
Here at the Vall d'Hebron Research Institute (VHIR) we promote biomedical research, innovation and teaching. Over 1,800 people are seeking to understand diseases today so the treatment can be improved tomorrow.
Research
We are working to understand diseases, to find out how they operate and to create better treatments for patients. Get to know about our groups and their lines of research.
People
People are the centre of the Vall d'Hebron Research Institute (VHIR). This is why we are bound by the principles of freedom of research, gender equality and professional attitudes that HRS4R promotes.
Clinical trials
Our work is not just basic or translational; we are leaders in clinical research. Enter and find about the clinical trials we are conducting and why we are a world reference in this field.
Progress
Our aim is to make the research carried out at the Vall d’Hebron Research Institute (VHIR) a driving force for transformation. How? By identifying new channels and solutions for the promotion of people's health and well-being.
Core facilities
We offer specialist support for researchers, internal and external alike, ranging from specific services to preparing complete projects. All this, from a perspective of quality and speed of response.
News
We offer you a gateway for staying up to date on everything going on at the Vall d’Hebron Research Institute (VHIR), from the latest news to future solidarity activities and initiatives that we are organising.
One of our current research goals is to develop a gene editing strategy that combines viral and non-viral vectors to treat Mitochondrial Neurogastrointestinal Encephalomyopathy (MNGIE), a rare disease due to inactivating mutations in the gene encoding thymidine phosphorylase, which has already demonstrated therapeutic efficacy in an animal model of the disease.
On the other hand, in collaboration with the Neuropediatrics group (Dra. F. Munell) and that of Dr. R. Hernández (University of Navarra), we are investigating another gene therapy approach based on high-capacity adenoviral vectors using a murine model of congenital muscular dystrophy type 1A (CMD1A).
Finally, in collaboration with the group of Dr. J. Verdaguer (University of Lleida), we are studying the mechanism of action, the cytolytic and pro-inflammatory activities, as well as several biomedical applications of a new family of peptides derived from intermediate filaments that were discovered by chance.
Development of a new gene therapy strategy based on high-capacity adenoviral vectors, which we carry out in collaboration with the group of Dr. Rubén Hernández, from the University of Navarra.
IP: Jordi Barquinero Mañez
IP: -
PhD student: Rocío Piñera Moreno Director/s: Jordi Barquinero Mañez, Lluis Tort Bardolet University: Universitat Autònoma de Barcelona Year: 2024
PhD student: Penelope Romero Duque Director/s: Francina Munell Casadesus, Jordi Barquinero Mañez University: Universidad Autònoma de Barcelona Year: 2022
PhD student: Marta Parés Casellas Director/s: Jordi Barquinero Mañez University: Universidad Autònoma de Barcelona Year: 2020
PhD student: Silvia Casacuberta Serra Director/s: Jordi Barquinero Mañez, Carmen Espejo Ruiz University: Universidad Autònoma de Barcelona Year: 2016
PhD student: Alba Gomez Morago Director/s: Jordi Barquinero Mañez, Carmen Espejo Ruiz University: Universidad Autònoma de Barcelona Year: 2012
PhD student: Javier Torres Torronteras Director/s: Ramon Martí Seves, Jordi Barquinero Mañez University: Universidad Autònoma de Barcelona Year: 2011
Over the course of two days, experts presented the latest advances in vectors, different gene modification techniques and their transfer to clinical practice.
